Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
Sodium cromoglicate is an antiasthmatic and antiallergenic drug used in inhalation therapy and commonly administered by a dry powder inhaler. In the present study we sought to examine the feasibility of producing nanoporous microparticles (NPMPs) of this hydrophilic material by adaptation of a spray drying process previously applied to hydrophobic drugs, and to examine the physicochemical and in vitro deposition properties of the spray dried particles in comparison to a commercial product. The storage stability of successfully prepared NPMPs was assessed under a number of conditions (4°C with dessicant, 25°C at 60% relative humidity and 25°C with dessicant). Spray dried sodium cromoglicate was amorphous in nature. NPMPs of sodium cromoglicate displayed superior aerodynamic properties resulting in improved in vitro drug deposition, as assessed by Andersen Cascade Impactor and twin impinger studies, in comparison to the commercial product, Intal. Deposition studies indicated that porosity and sphericity were important factors in improving deposition properties. The optimum solvent system for NPMP production was water:methanol:n-butyl acetate, as spherical NPMPs spray dried from this solvent system had a higher respirable fraction than non-spherical NPMPs of sodium cromoglicate (spray dried from methanol:n-butyl acetate), non-porous sodium cromoglicate (spray dried from water) and micronised sodium cromoglicate (Intal). While particle morphology was altered by storage at high humidity (60% RH) and in vitro deposition performance deteriorated, it was possible to maintain NPMP morphology and aerosolisation performance by storing the powder with dessicant.
School of Pharmacy and Pharmaceutical Sciences, Trinity College, University of Dublin, Dublin 2, Ireland.
Lorraine M
LM
Nolan
Jianhe
J
Li
Lidia
L
Tajber
Owen I
OI
Corrigan
Anne Marie
AM
Healy
D000280:Administration, Inhalation; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D055598:Chemical Phenomena; D004205:Cromolyn Sodium / Q000737:chemistry*; D003890:Desiccation; D004339:Drug Compounding / Q000379:methods*; D004355:Drug Stability; D058995:Dry Powder Inhalers; D005079:Excipients / Q000737:chemistry*; D006813:Humidity; D057927:Hydrophobic and Hydrophilic Interactions; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders; D012997:Solvents
D018927:Anti-Asthmatic Agents; D005079:Excipients; D011208:Powders; D012997:Solvents; D004205:Cromolyn Sodium